Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 26.71B, Biogen(BIIB) trades at $182.10. The stock has a price-to-earnings ratio of 16.61.
As of 2025-11-30, Biogen(BIIB) stock has fluctuated between $180.69 and $182.74. The current price stands at $182.10, placing the stock +0.8% above today's low and -0.4% off the high.
The Biogen(BIIB)'s current trading volume is 566.07K, compared to an average daily volume of 2.16M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $185.17 and a 52-week low of $110.04.
In the last year, Biogen(BIIB) shares hit a 52-week high of $185.17 and a 52-week low of $110.04.
BIIB News
Biogen (BIIB) just announced a new research partnership with Dayra Therapeutics focused on developing oral macrocyclic peptides for immunological conditions. Th...
Biogen Inc.‘s (NASDAQ:BIIB) partner Eisai Co., Ltd, on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulati...
Eisai Co. (ESAIY) and Biogen (BIIB) announced that Eisai has completed the rolling submission of the Supplemental Biologics License Application to the U.S. FDA...
Analyst ratings
50%
of 36 ratingsMore BIIB News
In November 2025, Biogen and Dayra Therapeutics announced a research collaboration to develop oral macrocyclic peptide therapies for immunological disorders, wi...
Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke...
(RTTNews) - Biogen Inc. (BIIB) said Monday that it has entered into a partnership with Dayra Therapeutics to discover and develop oral macrocyclic peptides for...
Shares of Biogen (BIIB) are up $7.51, or 4% to $182.81 in pre-market trading after Novo Nordisk (NVO) announced that the 2-year primary analysis of evoke and ev...